Skip to content

Abdominal pain on Wegovy, Zepbound, Ozempic and other GLP-1 medicines

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Ozempic stomach pain and abdominal pain on other GLP-1 medicines need prompt medical attention if the pain is persistent or severe, sometimes radiating to the back, because the labels describe that as a sign of acute pancreatitis. All eight labels list abdominal pain in their tables: 20% of adults on Wegovy 2.4 mg against 10% on placebo, and 9% to 10% on Zepbound against 5%.

Key takeaways

  • Persistent or severe abdominal pain, with or without vomiting, needs prompt medical attention. Don't wait to see if it settles.
  • The labels describe that pain, sometimes radiating to the back, as a sign of acute pancreatitis.
  • If you believe it's an emergency, call 911.
  • Each label also warns of acute gallbladder disease, meaning gallstones and gallbladder inflammation.
  • For milder discomfort, tell your prescriber, sooner if it follows a dose increase and doesn't ease.

How often it was reported in the label's trials

Zepbound: Table 1: Adverse Reactions (≥2% and Greater than Placebo) in ZEPBOUND-Treated Adults with Obesity or Overweight in Weight Reduction and Long-term Maintenance Trials (Study 1 and Study 2) · Pool of two randomized, double-blind, placebo-controlled weight reduction trials (Study 1 and Study 2) that included 2,519 adults with obesity or overweight, with or without type 2 diabetes, treated with Zepbound for up to 72 weeks plus a 4-week off-drug follow-up period.
ReactionPlacebon=9585 mgn=63010 mgn=94815 mgn=941
Abdominal Pain5%9%9%10%

FDA label: Zepbound, Revised: 8/2026 (DailyMed version 40)

Mounjaro: Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials Reported in ≥5% of MOUNJARO-treated Adult Patients with Type 2 Diabetes Mellitus · Pool of two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 monotherapy and SURPASS-5 added to basal insulin with or without metformin); 718 patients exposed to Mounjaro for a mean of 36.6 weeks. Hypoglycemia is not included.
ReactionPlacebon=2355 mgn=23710 mgn=24015 mgn=241
Abdominal Pain4%6%5%5%

FDA label: Mounjaro, Revised: 8/2026 (DailyMed version 40)

Wegovy: Table 3. Adverse Reactions (≥2% and Greater Than Placebo) in WEGOVY 2.4 mg Injection-treated Adults with Obesity or Overweight for Weight Reduction · Adults with obesity or overweight in 3 randomized, double-blind, placebo-controlled trials, treated with Wegovy 2.4 mg injection for up to 68 weeks plus a 7-week off-drug follow-up. The label shows '<1' for placebo eructation. The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 3: Wegovy N=403, placebo N=402). Abdominal pain, fatigue, gastritis and dysesthesia are grouped terms.
ReactionPlacebon=1261Wegovy injection 2.4 mg once weeklyn=2116
Abdominal Pain10%20%
Wegovy: Table 4. Adverse Reactions (2% and Greater Than WEGOVY 2.4 mg and Placebo) in WEGOVY 7.2 mg Injection-treated Adults with Obesity for Weight Reduction · Adults with obesity (BMI of 30 or more) in two 72-week, double-blind, randomized, placebo-controlled, 3-armed trials (Study 8 and Study 9, the second in patients with type 2 diabetes). Dysesthesia, abdominal pain, fatigue and dizziness are grouped terms.
ReactionPlacebon=303Wegovy injection 2.4 mg once weeklyn=304Wegovy injection 7.2 mg once weeklyn=1311
Abdominal pain7%9%12%
Wegovy: Table 5. Adverse Reactions (≥3% and Greater than Placebo) in WEGOVY 2.4 mg Injection-treated Pediatric Patients Aged 12 Years and Older with Obesity for Weight Reduction · Pediatric patients aged 12 years and older with obesity in a 68-week, double-blind, randomized, placebo-controlled trial of Wegovy 2.4 mg injection.
ReactionPlacebon=67Wegovy injection 2.4 mg once weeklyn=133
Abdominal Pain6%15%

FDA label: Wegovy, Revised: 6/2026 (DailyMed version 19)

Ozempic: Table 1. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of OZEMPIC-Treated Patients with Type 2 Diabetes Mellitus · Adults with type 2 diabetes in 2 placebo-controlled trials (1 monotherapy trial and 1 trial in combination with basal insulin); mean duration of exposure to Ozempic was 32.9 weeks. The table excludes hypoglycemia.
ReactionPlacebon=262Ozempic 0.5 mgn=260Ozempic 1 mgn=261
Abdominal pain4.6%7.3%5.7%

FDA label: Ozempic, Revised: 5/2026 (DailyMed version 20)

Foundayo: Table 1: Adverse Reactions Reported in ≥5% of FOUNDAYO-treated Adult Patients with Obesity or Overweight (With or Without Type 2 Diabetes) in Pool of Placebo-Controlled Trials (Trials 1 and 2) · Pool of two randomized, double-blind, placebo-controlled weight management trials (Trials 1 and 2) that included 3155 adults with obesity or overweight, with or without type 2 diabetes, treated with Foundayo once daily for up to 72 weeks plus a 2-week off-drug follow-up period.
ReactionPlacebon=15765.5 mgn=10519 mgn=105517.2 mgn=1049
Abdominal pain7%13%14%14%

FDA label: Foundayo, Revised: 7/2026 (DailyMed version 10)

Rybelsus: Table 2. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of Semaglutide Tablets-Treated Patients with Type 2 Diabetes Mellitus · Adults with type 2 diabetes in 2 placebo-controlled trials of semaglutide tablets (Rybelsus); mean duration of exposure was 41.8 weeks. The table excludes hypoglycemia.
ReactionPlacebon=362Semaglutide tablets 7 mgn=356Semaglutide tablets 14 mgn=356
Abdominal Pain4%10%11%

FDA label: Rybelsus, Revised: 1/2026 (DailyMed version 14)

Saxenda: Table 2. Adverse Reactions Occurring in ≥2% of SAXENDA-treated Adult Patients and More Frequently than Placebo · Adults with overweight or obesity in 5 double-blind, placebo-controlled trials, treated for up to 56 weeks (3 trials), 52 weeks (1 trial) and 32 weeks (1 trial). The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 2: Saxenda N=423, placebo N=212), defined as blood glucose below 54 mg/dL with or without symptoms.
ReactionPlacebon=1941Saxendan=3384
Abdominal Pain3.1%5.4%

FDA label: Saxenda, Revised: 6/2026 (DailyMed version 22)

Trulicity: Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials That Occurred in ≥5% of TRULICITY-Treated Adult Patients with Type 2 Diabetes Mellitus · Pool of placebo-controlled trials that included 1,670 adults with type 2 diabetes exposed to Trulicity 0.75 mg or 1.5 mg, with a mean duration of exposure of 23.8 weeks. Hypoglycemia is excluded.
ReactionPlacebon=5680.75 mgn=8361.5 mgn=834
Abdominal Pain4.9%6.5%9.4%

FDA label: Trulicity, Revised: 3/2026 (DailyMed version 62)

Each medicine's figures come from its own trials, which differ in dose, length and who took part. They are not a head-to-head comparison.

If you have stomach pain on a GLP-1 medicine, the first question is how bad it is. Persistent or severe abdominal pain, with or without vomiting, needs prompt medical attention. Don’t wait to see whether it settles, and don’t decide about your next dose alone. If you believe it’s an emergency, call 911.

Abdominal pain is in every GLP-1 label’s table of common reactions. It’s also the symptom the labels use to describe two serious conditions. This page covers both sides: the routine figures and the warnings.

How often do the labels report abdominal pain?

Each figure is the share of trial patients who reported it, next to the placebo group from the same trials. A placebo group gets an inactive treatment instead of the medicine.

  • Wegovy 2.4 mg injection (adults, three weight reduction trials): 20%, with 10% on placebo. The label notes this is a grouped term covering several kinds of abdominal pain. In the 7.2 mg trials: 12% on 7.2 mg, 9% on 2.4 mg and 7% on placebo.
  • Foundayo (adults with obesity or overweight, two pooled trials): 13% at 5.5 mg, 14% at 9 mg and 14% at 17.2 mg, with 7% on placebo.
  • Rybelsus (adults with type 2 diabetes, two trials; the label also covers Ozempic tablets): 10% at 7 mg and 11% at 14 mg, with 4% on placebo.
  • Zepbound (adults with obesity or overweight, two pooled trials): 9% at 5 mg, 9% at 10 mg and 10% at 15 mg, with 5% on placebo.
  • Trulicity (adults with type 2 diabetes, pooled trials): 6.5% at 0.75 mg and 9.4% at 1.5 mg, with 4.9% on placebo.
  • Ozempic injection (adults with type 2 diabetes, two trials): 7.3% at 0.5 mg and 5.7% at 1 mg, with 4.6% on placebo.
  • Mounjaro (adults with type 2 diabetes, two pooled trials): 6% at 5 mg, 5% at 10 mg and 5% at 15 mg, with 4% on placebo. In its cardiovascular outcomes trial, the label reports abdominal pain in 10% of patients on Mounjaro.
  • Saxenda (adults, five trials): the table has two rows. Abdominal pain: 5.4%, with 3.1% on placebo. Upper abdominal pain: 5.1%, with 2.7% on placebo.

In younger patients, the Wegovy label reports 15% on 2.4 mg and 6% on placebo in adolescents with obesity. The Mounjaro label reports 22% at 5 mg and 15% at 10 mg, with 9% on placebo, in its 30-week trial in patients aged 10 and older with type 2 diabetes. Saxenda’s adolescent table lists “abdominal discomfort” at 4.8%, with 0.8% on placebo.

The labels count this reaction differently. Wegovy groups several terms into one row, and Saxenda splits them into two. That alone means you can’t compare the rows between medicines, even before you consider how the trials differ.

The timing sentences in the labels name nausea, vomiting and diarrhea. Only Wegovy’s covers gastrointestinal (stomach and bowel) reactions as a group, saying they were most frequently reported during dosage escalation, the weeks when the dose is being raised.

The pancreatitis warning

All eight labels carry a warning on acute pancreatitis, an inflammation of the pancreas. The Wegovy, Ozempic and Saxenda labels use nearly the same sentence: observe patients carefully for signs and symptoms, “which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue” the medicine “and initiate appropriate management.”

The Zepbound, Mounjaro and Trulicity labels state that acute pancreatitis, “including fatal and non-fatal hemorrhagic or necrotizing pancreatitis,” has been observed in patients treated with GLP-1 receptor agonists or the medicine itself. Hemorrhagic and necrotizing pancreatitis are severe forms that involve bleeding or tissue death.

Confirmed cases in the trials were few. Zepbound’s pooled trials: 0.2% on Zepbound and 0.2% on placebo. Saxenda’s adult trials: 9 of 3,291 patients on Saxenda (0.3%) and 2 of 1,843 on placebo (0.1%). Wegovy’s adult weight reduction trials: 4 patients on Wegovy and 1 on placebo.

The gallbladder warning

Each label also warns of acute gallbladder disease, meaning gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis). Here’s what the trials reported:

  • Saxenda, adults: gallstones in 2.2% on Saxenda and 0.8% on placebo; cholecystitis in 0.8% and 0.4%. The label says most Saxenda patients with these events required gallbladder removal.
  • Wegovy, adults: gallstones in 1.6% on the injection and 0.7% on placebo; cholecystitis in 0.6% and 0.2%. In the adolescent trial, gallstones appear in the table at 4% on Wegovy and 0% on placebo.
  • Zepbound: gallstones in 1.1% and 1% on placebo; cholecystitis in 0.7% and 0.2%.
  • Foundayo: gallstones in 1% and 0.7% on placebo.

When to get help

Persistent or severe abdominal pain, with or without vomiting, needs prompt medical attention. The labels leave the decision to stop the medicine to the clinician who suspects pancreatitis. So don’t wait to see whether it settles, and don’t decide about your next dose alone. If you believe it’s an emergency, call 911.

For milder discomfort, tell your prescriber at your next contact, and sooner if it follows a dose increase and doesn’t ease. See also dyspepsia, nausea, vomiting, constipation and the side effects overview.

Frequently asked questions

Is stomach pain a side effect of Ozempic?

Yes, abdominal pain is in the Ozempic injection label's table. In two placebo-controlled trials in adults with type 2 diabetes, 7.3% of patients on 0.5 mg and 5.7% on 1 mg reported it, compared with 4.6% on placebo. The same label warns that persistent or severe abdominal pain can be a sign of acute pancreatitis, so get that kind of pain checked promptly.

How do I know if abdominal pain is pancreatitis?

You can't tell from a web page, and the labels don't ask patients to. They describe the signs prescribers watch for: persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting. Pain like that needs prompt medical attention so a clinician can assess it.

How common is pancreatitis on GLP-1 medicines?

Uncommon in the trials. In Zepbound's pooled weight reduction trials, 0.2% of patients on Zepbound and 0.2% on placebo had acute pancreatitis confirmed by adjudication, a formal review of each case. In Saxenda's adult trials it was confirmed in 0.3% of patients on Saxenda and 0.1% on placebo. The labels also describe fatal and non-fatal cases reported with GLP-1 receptor agonists.

Can a GLP-1 cause gallbladder problems?

Every label we track carries a warning on acute gallbladder disease. In Saxenda's adult trials, gallstones were reported by 2.2% of patients on Saxenda and 0.8% on placebo. In Wegovy's adult weight reduction trials, the figures were 1.6% on the injection and 0.7% on placebo. Zepbound's pooled trials reported gallstones in 1.1% of treated patients and 1% on placebo.

Sources (8)

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.